Seoul Biotech Startup to Partner with Global Pharma, US VCs at BIO USA 2025

Seoul Bio Hub successfully participated in 『BIO USA 2025』 held in Boston, USA, with 10 bio startups based in Seoul, establishing a bridgehead for global market entry. Under cooperation with Invest Seoul, Seoul Bio Hub selected promising companies in the pharmaceutical bio, medical device, and digital healthcare sectors early this year, and provided customized consulting, advanced IR materials, and pitching skill enhancement programs, thereby increasing the effectiveness of partnering. The participating companies were Galux, Medimap Bio, VSPHARMTECH, CELLABMED, CELKI AI, AstroGent, ABLEVIS, EXOSOLENCE, Cureverse, and Protina. They showcased their technologies through individual booths at the integrated Korea Pavilion operated by Seoul Bio Hub and actively conducted local business meetings using the partnering platform. In particular, the 'Seoul Bio Forum' hosted by Invest Seoul on the first day of BIO USA garnered significant attention, with over 130 attendees from global pharmaceutical companies, investment firms, and industry stakeholders, including AstraZeneca, Pfizer, Obimed, Nvidia, UCLA, and Mayo Clinic. The participating companies introduced their businesses and technologies through IR presentations at this event, and continued in-person follow-up meetings with pre-arranged online meeting partners, exploring various cooperation opportunities such as investment, technology transfer, and sales contracts. Key achievements included Galux, which discussed licensing for its AI-based antibody design platform; VSPHARMTECH, which continued technology transfer negotiations for its radiation sensitizer; CELLABMED, which introduced technology transfer for solid tumor CAR-T therapies and its CDMO business; CELKI AI, which discussed cooperation with Harvard Medical School and others using its AI multi-omics analysis technology; and AstroGent, which completed Phase 3 clinical trials for its autism spectrum disorder treatment. Additionally, ABLEVIS (AI pathology biomarker solution), EXOSOLENCE (extracellular vesicle-based drug delivery system), Cureverse (Alzheimer's and multiple sclerosis treatments), and Protina (protein big data and antibody drug development) also garnered attention from global partners. A total of over 150 partnering meetings were conducted during BIO USA 2025, and cooperation discussions are expected to continue even after the event concludes. Seoul Bio Hub plans to continue supporting companies in generating achievements and, furthermore, intends to promote 'Global Open Innovation' for discovering US startups through cooperation with Celltrion, thereby contributing to the expansion of Seoul's bio-industry ecosystem.